News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cancer Prevention Pharmaceuticals, Inc. Release: Phase 3 Familial Adenomatous Polyposis (FAP) Trial Now Open For Enrollment


12/5/2013 9:25:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TUCSON, Ariz., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Cancer Prevention Pharmaceuticals, Inc., (CPP) announced today the launch of a double-blind, randomized, Phase III trial of the efficacy and safety of CPP-1X/sulindac (eflornithine/sulindac) compared with CPP-1X and sulindac as single agents in 150 patients with Familial Adenomatous Polyposis. Each patient will receive daily treatment for two years to minimize the occurrence and/or recurrence of problematic polyps and tumors associated with this debilitating disease. The trial is being conducted at 8 North American and 4 European clinical trial sites.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES